Biotech Boom Reshapes Medical Tourism in Middle East and Africa

Biotech investment flows from the Gulf to East and West Africa are reshaping medical tourism, with the United Arab Emirates, Rwanda and several African biotech firms positioning themselves as new destinations for advanced treatments, vaccines and precision medicine. Public materials and reporting show the UAE has emphasised precision medicine, genomics and cell-based therapies, while projects such as a planned BioNTech mRNA vaccine manufacturing facility near Kigali and initiatives hosted by HealthTech Hub Africa are building research and production capacity across the region.

"Biotech investments from Dubai to Kigali are turning parts of the Middle East and Africa into emerging hubs for advanced treatment, vaccines and precision medicine tourism," wrote Vanessa Buasini.

Dubai has promoted bundled surgery, rehabilitation and luxury accommodation through entities such as Dubai Healthcare City and other free zones, seeking to capture patients from Asia, Africa, Europe and the Gulf. Reports cited in investment guides say wellness visitors spent "several billions of dollars in the country in 2022," and authorities highlight cancer care, orthopedics, fertility, cosmetic and dental procedures as core specialties that now increasingly include biotech-enabled offerings. Abu Dhabi and Dubai have expanded research and innovation centres that support access to gene transfer therapies and advanced biologics, framing those capabilities as reasons patients need not travel to North America or Western Europe.

Regional projects and research hubs

• Rwanda: Financial institutions and development partners have approved funding for a BioNTech mRNA vaccine manufacturing facility near Kigali, described in project documents as both a production site and a regional R&D platform meant to strengthen Africa’s vaccine ecosystem.
• HealthTech Hub Africa: Hosted in Kigali, the hub has supported dozens of digital health companies working on cardiovascular disease, breast cancer and AI-driven diagnostics, and showcased telemedicine and remote-monitoring startups in 2025 events.
• African Development Bank: Backing regional projects to create centres of excellence for biomedical engineering and e-health across East Africa, with stated aims to stimulate intra-African medical travel for more complex imaging and device-based procedures.
• Yemaachi Biotech and the African Cancer Atlas: Ghana-based Yemaachi leads a clinico-genomic platform integrating sequencing and standardized clinical data for breast cancer across multiple African countries, a project observers say could accelerate regional access to precision oncology.

Elsewhere, firms in South Africa and Ghana are advancing mRNA platforms and immunotherapies aimed at tuberculosis and high-prevalence cancers, while South African hospitals remain regional magnets for complex oncology, cardiac surgery and transplant care. Observers note that regulatory reforms, participation in continental medicines agencies and harmonised clinical-trial rules are being promoted to ease cross-border scaling for biotech firms and patient movement between hubs.

Outlook

Policymakers frame biotech-linked hubs as drivers of skilled jobs, foreign currency and ancillary industries such as clinical trials, logistics and medical training. For international patients the selling points are lower costs relative to traditional destinations, shorter flights, cultural proximity and the possibility of participating in locally developed vaccine or therapeutic programmes. If planned facilities—most notably the BioNTech site near Kigali—and the expansion of precision-medicine offerings in Abu Dhabi and Dubai proceed as described in investment materials, analysts expect a gradual reorientation of some medical travel toward Middle Eastern and African centres over the coming years.